These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1283721)

  • 1. [Peptides from the principal neutralizing and CD4-binding domain: similar immunoreactive properties and structure pattern].
    Meshcheriakova DV; Andreev SM; Sidorova MV; Vafina MG; Az'muko AA; Petrukhina AO; Khaitov RM
    Vestn Ross Akad Med Nauk; 1992; (9-10):47-52. PubMed ID: 1283721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies of HIV-1 positive subjects and experimentally immunized primates and rodents bind to sequence divergent regions of the third variable domain (V3) of gp120.
    Boudet F; Girard M; Theze J; Zouali M
    Int Immunol; 1992 Feb; 4(2):283-94. PubMed ID: 1377948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19- to 36-residue) synthetic peptides.
    Neurath AR; Strick N; Lee ES
    J Gen Virol; 1990 Jan; 71 ( Pt 1)():85-95. PubMed ID: 1689372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A potent, neutralizing human monoclonal antibody against a unique epitope overlapping the CD4-binding site of HIV-1 gp120 that is broadly conserved across North American and African virus isolates.
    Pinter A; Honnen WJ; Racho ME; Tilley SA
    AIDS Res Hum Retroviruses; 1993 Oct; 9(10):985-96. PubMed ID: 7506556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
    Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthetic peptides and anti-peptide antibodies as probes to study interdomain interactions involved in virus assembly: the envelope of the human immunodeficiency virus (HIV-1).
    Neurath AR; Strick N; Jiang S
    Virology; 1992 May; 188(1):1-13. PubMed ID: 1373549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for non-V3-specific neutralizing antibodies that interfere with gp120/CD4 binding in human immunodeficiency virus 1-infected humans.
    Kang CY; Nara P; Chamat S; Caralli V; Ryskamp T; Haigwood N; Newman R; Köhler H
    Proc Natl Acad Sci U S A; 1991 Jul; 88(14):6171-5. PubMed ID: 2068099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-reactivity between autoimmune anti-U1 snRNP antibodies and neutralizing epitopes of HIV-1 gp120/41.
    Douvas A; Takehana Y
    AIDS Res Hum Retroviruses; 1994 Mar; 10(3):253-62. PubMed ID: 7517148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymphocytotropic strains of HIV type 1 when complexed with enhancing antibodies can infect macrophages via Fc gamma RIII, independently of CD4.
    Trischmann H; Davis D; Lachmann PJ
    AIDS Res Hum Retroviruses; 1995 Mar; 11(3):343-52. PubMed ID: 7540399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pattern of antibody response against the V3 loop in children with vertically acquired immunodeficiency virus type 1 (HIV-1) infection.
    De Rossi A; Zanotto C; Mammano F; Ometto L; Del Mistro A; Chieco-Bianchi L
    AIDS Res Hum Retroviruses; 1993 Mar; 9(3):221-8. PubMed ID: 7682425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [An enzyme-linked immunosorbent assay determining anti-principal neutralizing determinant antibodies using synthetic peptides deduced from cDNA sequences of HIV-1 V3 loop domain].
    Ishimoto S; Fujimura Y; Yamanaka T; Shimoyama T; Nishida S; Matsuoka H; Nishikawa K; Yoshioka A; Narita N; Honda M
    Rinsho Ketsueki; 1995 Mar; 36(3):193-9. PubMed ID: 7540222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of antibody assays for identifying and distinguishing recent from long-term HIV type 1 infection.
    Parekh BS; Pau CP; Kennedy MS; Dobbs TL; McDougal JS
    AIDS Res Hum Retroviruses; 2001 Jan; 17(2):137-46. PubMed ID: 11177393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody responses to HIV-1 envelope and gag epitopes in HIV-1 seroconverters with rapid versus slow disease progression.
    Zwart G; van der Hoek L; Valk M; Cornelissen MT; Baan E; Dekker J; Koot M; Kuiken CL; Goudsmit J
    Virology; 1994 Jun; 201(2):285-93. PubMed ID: 7514319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of human immunodeficiency virus neutralizing antibodies using fusion complexes.
    Zipeto D; Matucci A; Ripamonti C; Scarlatti G; Rossolillo P; Turci M; Sartoris S; Tridente G; Bertazzoni U
    Microbes Infect; 2006 May; 8(6):1424-33. PubMed ID: 16702010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A CD4-derived peptide carrier blocks acute HIV-1 infection in vitro and binds to gp120 in the presence of Walter-Reed stage 1-6 HIV+ sera.
    Ghetie V; Wheeler T; Scott D; Uhr JW; Vitetta ES
    AIDS Res Hum Retroviruses; 1992 Nov; 8(11):1945-8. PubMed ID: 1489581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1.
    Berman PW; Matthews TJ; Riddle L; Champe M; Hobbs MR; Nakamura GR; Mercer J; Eastman DJ; Lucas C; Langlois AJ
    J Virol; 1992 Jul; 66(7):4464-9. PubMed ID: 1602554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relative reactivity of the V3 loop PND of HIV-1 subtypes A, B, C, D, and F with sera from selected Ugandan localities.
    Riley JP; Pestano GA; Hosford K; Francis C; Xie JM; Mugyenyi P; Kataaha P; Katongole-Mbidde E; Anokbonggo WW; Guyden J
    Arch Virol; 1995; 140(8):1393-404. PubMed ID: 7544970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
    Klasse PJ; McKeating JA; Schutten M; Reitz MS; Robert-Guroff M
    Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in the reactivity and neutralizing activity of a type-specific neutralizing monoclonal antibody induced by interaction of soluble CD4 with gp120.
    Maeda Y; Matsushita S; Hattori T; Murakami T; Takatsuki K
    AIDS Res Hum Retroviruses; 1992 Dec; 8(12):2049-54. PubMed ID: 1493053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.